PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsSilencing a prostate cancer gene kills tumour cells

BioNews

Silencing a prostate cancer gene kills tumour cells

Published 1 June 2018 posted in News and appears in BioNews 952

Author

Dr Massimo Ganassi

PET BioNews

A recent study identifies a new molecule as a potential target for prostate cancer therapy...

A recent study identifies a new molecule as a potential target for prostate cancer therapy.

Prostate cancer is the most common cancer in UK men. Because prostate cells – healthy and cancerous – depend on male hormones (androgens) to function, it is routinely treated with drugs that suppress androgens or their receptors (ARs). 

However, cancer cells can become resistant to androgen suppression therapies over time, and the tumour can then progress and spread. Androgen suppression can also have significant side effects including loss of muscle mass and sexual function.

'The androgen receptor is an important target in prostate cancer…This study identifies a feedback loop that we could potentially disrupt as an alternative to blocking the androgen receptor directly,' said study senior author Dr Arul Chinnaiyan, director of the Michigan Centre for Translational Pathology in Ann Arbor, Michigan.

The team used a technique called transcriptome analysis on prostate cancer cell lines and tissues, to study the role of a group of RNA molecules, whose function is not yet well understood: long non-coding RNAs (lncRNAs).

The study, published in Nature Genetics, revealed that a novel lncRNA which they named ARLNC1, is regulated by AR signalling and is expressed almost exclusively in prostate tumours.

Suppressing ARLNC1 expression – through direct RNA binding – in cultured cancer cells reduced the levels of AR effectors and caused a significant increase of tumour cell death. The result was replicated in an in vivo model: blocking ARLNC1 in mice significantly reduced tumour size and growth.

Based on their results, the authors suggest that ARLNC1 functions in regulating AR signalling and may be involved in prostate cancer metastatic progression. As such ARLNC1 may be a promising targeting for combined cancer treatment.

Related Articles

PET BioNews
News
1 May 2020 • 2 minutes read

Breast and ovarian cancer drug repurposed to treat prostate cancer

by Javier Bautista

A drug already used to treat breast and ovarian cancer can also significantly delay the progression of prostate cancer...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
12 July 2019 • 2 minutes read

NHS approves gene-silencing drug for rare hereditary condition

by Charlotte Spicer

The first RNA-based therapy has been approved for NHS use in England...

Image by Christoph Bock/Max Planck Institute for Informatics via Wikimedia Commons. Depicts a DNA molecule that is methylated on both strands on the centre cytosine.
CC BY-SA 3.0
Image by Christoph Bock/Max Planck Institute for Informatics via Wikimedia Commons. Depicts a DNA molecule that is methylated on both strands on the centre cytosine.
News
19 October 2018 • 2 minutes read

Epigenetic test sorts fatal from manageable prostate cancer

by Isobel Steer

Researchers have identified a DNA methylation signature that can identify aggressive prostate cancer, with up to 92 percent accuracy...

PET BioNews
News
3 August 2018 • 2 minutes read

New class of drug puts cancer cells to sleep

by Dr Jamie Heather

Australian researchers have developed a new kind of anti-cancer drug, which halted cancer cells in their tracks in mice...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
20 July 2018 • 2 minutes read

Gene therapy treats deadly Gaucher disease in the womb

by Isobel Steer

Gene therapy has successfully treated a disorder in mice while still inside the womb, according to a study published in Nature Medicine...

PET BioNews
News
3 May 2018 • 2 minutes read

'Master activator' gene for cancer spread found

by Dr Molly Godfrey

A gene that plays a major role in promoting metastasis — the spread of cancer around the body — has been identified...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
15 May 2017 • 2 minutes read

Cancer fusion genes targeted with CRISPR

by Sarah Pritchard

Aggressive human prostate and liver tumours have been shrunk in mice by targeting a ‘fused’ gene mutation using CRISPR/Cas9...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
23 January 2017 • 2 minutes read

Genetic fingerprint identifies aggressive prostate cancer

by Annabel Slater

Canadian scientists have identified a genetic fingerprint that indicates which prostate cancer tumours may develop into a more aggressive form of the disease after treatment...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Three genes give evolutionary insights into human brain size

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

15 August 2022 • 2 minutes read

Call to end ban on HIV-positive partner gamete 'donation'

15 August 2022 • 2 minutes read

Melanoma invades new tissues using nerve cell gene

15 August 2022 • 2 minutes read

Exceeding alcohol limits could damage DNA and accelerate ageing

15 August 2022 • 2 minutes read

Blood cell gene mutations affect mitochondria, increasing cardiovascular disease risk

15 August 2022 • 2 minutes read

Jumping gene helps immune system fight viruses

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856